PRESENT POSITIONS Professor of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver Clinical Director, Pulmonary Hypertension Center, University of Colorado Denver Chairman, Pharmacy & Therapeutics Committee, University Hospital, University of Colorado Denver Member, Dept. of Medicine QA/QI Program University of Colorado Denver Alternate Member, ICR Variance Committee University of Colorado Denver Member, Planning Committee, American Thoracic Society, 2000-2002 Member, Scientific Advisory Board, Pulmonary Hypertension Association, 1994-2001 Chairman, Nominations Committee, Scientific Advisory Board, Pulmonary Hypertension Association, 2001 Chairman, Scientific Meeting Committee, Scientific Advisory Board, Pulmonary Hypertension Association, 2001-2002 SELECTED PUBLICATIONS

1. Fassler CA, Rodriquez M, Badesch DB, Stone WJ, Marini JJ. Magnesium toxicity as a cause of hypotension and hypoventilation. Occurence in patients with normal renal function. Arch Intern Med 145:1604-1606;1985.
2. Truwit JD, Badesch DB, Savage AM, Shelton M. Vibrio vulnificus bacteremia with endocarditis. Southern Med J 80:1457;1987.
3. Badesch DB, King TE, Schwarz MI. Acute eosinophilic pneumonia: A hypersensitivity phenomenon? Am Rev Respir Dis 139:249-252;1989.
4. Badesch DB, Collins T, King TE. Rapidly progressive interstitial lung disease in a 58-year-old man. Seminars in Respir Med 10:101-104;1989.
5. Badesch DB, McClellan M, Wheeler A, Archer P, Schwarz MI, Petty T. A model for the objective assessment of clinical training programs: The initial application to two pulmonary fellowship programs. Am Rev Respir Dis 140:1136-1142;1989.
6. Badesch DB, Zapp LM, Westcott JY, Hester J, Orton EC, Voelkel NF, Stenmark KR. Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. Am J Respir Cell and Mol Biol 1:489-498;1989.
7. Badesch DB, Lee PDK, Parks WC, Stenmark KR. Insulin-like growth factor I stimulates elastin synthesis by bovine pulmonary arterial smooth muscle cells. Biochem Biophys Res Comm 160:382-387;1989.
8. Durmowicz AG, Badesch DB, Parks WC, Stenmark KR. Hypoxia-induced inhibition of tropoelastin synthesis by neonatal calf pulmonary artery smooth muscle cells. Am J Respir Cell and Mol Biol 5:464-469; 1991.
9. Dempsey EC, Stenmark KR, McMurtry IF, O'Brien RF, Voelkel NF, Badesch DB. Insulin-like growth factor I and protein kinase C activation stimulate pulmonary artery smooth muscle cell proliferation through separate but synergistic pathways. J Cell Physiol 144:159-165;1990.
10. Rodman D, Stelzner T, Hanley M, Badesch DB, Dempsey E, Terada L. The pulmonary academic "transitional track" - A view from junior faculty. Am Rev Respir Dis 141:1389-1390;1990.
11. Fernandez E, Weiner P, Meltzer E, Lutz MM, Badesch DB, Cherniack RM. Sustained improvement in gas exchange following negative pressure ventilation for 8 hours/day on two successive days in chronic airflow limitation. Am Rev Respir Dis 144:390-394;1991.
12. Stenmark KR, Aldashev A, Orton EC, Durmowicz AG, Badesch DB, Parks WC, Voelkel NF, Reeves JT. Cellular adaptation during chronic neonatal hypoxic pulmonary hypertension. Am J Physiol 261:97-104;1991.
13. Perkett EA, Badesch DB, Roessler M, Stenmark KR, Meyrick B. Insulin-like growth factor-I and vascular remodelling in a sheep model of chronic pulmonary hypertension. Am Rev Respir Cell Molec Biol 6:82-87;1992.
14. Badesch DB, Wynne KR, Bonvallet S, Voelkel NF, Ridgeway C, Groves BM. Hypothyroidism in primary pulmonary hypertension. Ann Intern Med 119:44-46;1993.
15. Stenmark KR, Badesch DB, Dempsey EC, Frid M, Parks WC, Mecham RP. Regulation of pulmonary vascular wall cell growth: developmental and site-specific heterogeneity. Eur Respir Rev 3:16,629-637;1993.
16. Badesch DB, Groves, BM. Current Therapeutic Options in Severe Pulmonary Hypertension. Seminars in Respir Med 15:482-489;1994.
17. Groves BM, Badesch DB, Dole W, Donnellan K, Wynne K, Robertson AD, Voelkel MD, Reeves JT. Acute hemodynamic effects of iloprost in primary (unexplained) pulmonary hypertension. Seminars in Respir Med 15:230-237;1994.
18. Tudor RM, Groves B, Badesch DB, Voelkel NF. Exhuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Amer J Pathol 144:275-285;1994.
19. Jones SD, Fullerton DA, Zamora MR, Badesch DB, Campbell DN, Grover FL. Transmission of lactobacillus pneumonia by a transplanted lung. Ann Thorac Surg 58:887-89;1994.
20. Dempsey EC, Badesch DB, Dobyns EL, Stenmark KR. Enhanced growth capacity of neonatal pulmonary artery smooth muscle cells in vitro: dependence on cell size, time from birth, insulin-like growth factor I, and auto-activation of protein kinase C. J Cell Physiol 160:469-81;1994.
21. Ivy D, Wiggins JW, Badesch DB, Kinsella JP, Kelminson L, Abman SH. Nitric oxide and prostacyclin treatment of an infant with primary pulmonary hypertension. J Am Col Cardiol 74:414-416;1994.
22. Badesch DB, Zamora M, Jones S, Campbell D, Fullerton DA. Independent ventilation and extracorporeal membrane oxygenation (ECMO) for severe unilateral pulmonary edema following single lung transplantation for primary (unexplained) pulmonary hypertension. Chest 107:1766-1770;1995.
23. Zamora MR, Fullerton DA, Campbell DN, Leone S, Diercks MJ, Fisher JH, Badesch DB, Grover FL. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients. Transplantation Proceedings 26:No. 5:Supplement 1:49-51;1994.
24. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn SD, Shortino D, Crow JW, for the Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. NEJM 334:296-301;1996.
25. Reeves JT, Gheen KM, Badesch DB. Variability in pulmonary hypertension: possible importance of genetic factors. (In Press, European J. Respiration, 1995).
26. Abraham WT, Raynolds MV, Gottschall B, Badesch DB, Wynne KM, Groves BM, Lowes BD, Bristow MR, Perryman MB, Voelkel NF. Importance of angiotensin-converting enzyme in pulmonary hypertension. Cardiology 86(suppl 1):9-15;1995.
27. Gass R, Fisher J, Badesch D, Zamora M, Weinberg A, Melsness H, Grover F, Tully JG, Fang FC. Donor-to-host transmission of mycoplasma hominis in lung allograft recipients. Clinical Infectious Diseases 22:567-8;1996.
28. Beaver TM, Brown J, Zamora MR, Weill D, Badesch DB. Colon perforation in lung transplant recipients. Ann Thorac Surg 62:839-843;1996.
29. Welsh CH, Hassell KL, Badesch DB, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 110:710-17;1996.
30. Grover FL, Fullerton DA, Zamora MR, Mills C, Ackerman B, Badesch D, Brown JM, Campbell DN, Chetham P, Dhaliwal A, Diercks M, Kinnard T, Niejadlik K, Ochs M. Lung transplantation: Past, present, and future. Am J Surg 173:523-533;1997.
31. Hinderliter AL, Park WW, Barst RJ, Rich S, Rubin LJ, Badesch DB, Groves BM, McGoon MD, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretksy BF, Koch G, Li Shu, Clayton LM, Jobsis MM, Blackburn SD, Crow JW, Long W, and the Primary Pulmonary Hypertension Study Group. Effects of chronic infusion of epoprostenol (prostacyclin) on echocardiographic measures of right heart structure and function in primary pulmonary hypertension. Circulation 95:1479-1486;1997.
32. Mann R, Badesch DB, Zamora M, Dreskin SC. Densensitization to trimethoprim-sulfamethoxazole following lung transplantation. Letter. Chest 111:1147;1997.
33. Lowes BD, Minobe W, Abraham WT, Riseq M, Bohlmeyer T, Quaife R, Roden RL, Dutcher DL, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR. Changes in gene expression in the intact human heart: down-regulation of a-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 100:2315-2324;1997.
34. Badesch DB, Zamora M, Fullerton D, Weill D, Tuder R, Grover F, Schwarz MI. Pulmonary capillaritis: A histologic form of acute lung allograft rejection. J Heart Lung Transplant 17:415-22;1998.
35. Bristow MR, Zisman LS, Lowes BD, Abraham WT, Badesch DB, Groves BM, Voelkel NF, Lynch DMB, Quaife RA. The pressure-overloaded right ventricle in pulmonary hypertension. Chest 114:July Supplement;1998.
36. Wynne K, Fagan K, Badesch DB. Primary pulmonary hypertension. Women’s Health in Primary Care 2:489-503;1999.
37. Tuder RM, Cool CD, Wright L, Geraci MW, Wang J, Abman SH, Wright L, Badesch DB, Voelkel. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159:1925-1932;1999.
38. Quaife RA, Lynch D, Badesch DB, Voelkel NF, Lowes BD, Robertson AD, Bristow MR. Right ventricular phenotypic characteristics in subjects with primary pulmonary hypertension or idiopathic dilated cardiomyopathy. J Card Fail 5(1):46-54;1999.
39. Langleben D, Barst RJ, Badesch DB, Groves BM, Tapson VF, Murali S, Bourge RC, Ettinger N, Shalit E, Clayton LM, Jobsis MM, Blackburn SD, Crow JW, Stewart DJ, Long W. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation 99(25):3266-71;1999.
40. Voelkel MA, Wynne KM, Badesch DB, Groves BM, Voelkel NF. Hyperuricemia in severe pulmonary hypertension. Chest. 2000 Jan;117(1):19-24.
41. Holcomb BW, Voelkel NF, Groves BM, Wynne K, Badesch DB. Primary pulmonary hypertension: Another non-hepatic manifestation of hepatitis C? (Manuscript in preparation)
42. Badesch DB, Tapson VF, McGoon MD, Brundage BH, LJ Rubin, Wigley FM, Rich S, Barst RJ, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized controlled trial. Annals of Internal Medicine 132:425-434;2000.
43. Badesch DB. Pulmonary Hypertension. Encyclopedia of Life Sciences. Accepted for publication December 1999. Currently published electronically at www.els.net.
44. Maloney JP, Fagan KA, Badesch DB, Groves B, Jacobs ER, Voelkel NF. Circulating levels of vascular endothelial growth factor are increased in primary pulmonary hypertension. Evidence for prostacyclin-related effects. (Manuscript in preparation)
45. Rich S, Rubin L,Walker AM, Schneeweiss S, Lucien Abenhaim for the SNAPH invesitgators (including Dr. Badesch). Anorexigens and Pulmonary Hypertension in the United States. Results from the Surveillance of North American Pulmonary Hypertension. Chest 870-874;2000.
46. Channick, RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: A randomized placebo-controlled study. Lancet 358:1119-23;2001.
47. McLaughlinVV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Brundage BH, Rubin LJ, Rich S, on behalf of the Treprostinol Study Group. Efficacy and Safety of Treprostinol: A Epoprostenol Analogue for Primary Pulmonary Hypertension. Manuscript to be submitted to Journal of Cardiovascular Pharmacology.
48. Lewis J. Rubin, MD; David B. Badesch MD, Robyn J. Barst, MD; Nazzareno Galiè, MD; Carol M. Black, MD; Anne Keogh, MD; Toma Pulido, MD; Adaani Frost, MD; Sébastien Roux, MD; Isabelle Leconte, PhD; Maurizio Rainisio, PhD; Frédéric Bodin, MD; Gérald Simonneau, MD on behalf of the BREATHE-1 Study Group. Bosentan in Patients with Pulmonary Arterial Hypertension: BREATHE-1, a Multicenter, Randomized, Placebo-Controlled Study. Manuscript in preparation for submission to NEJM.